Pharmaceutical Dissolution Testing Products and Services

Dissolution testing allows for the examination and prediction of the in-vitro behavior of pharmaceutical formulations. Drug release behavior of pre-formulations is made possible by the use of specialized dissolution equipment. By dissolution testing, a researcher can simulate the behavior of capsule, bead, and enteric-coated tablets in-vitro.

Important Applications of Dissolution Testing

  • Quality Control
  • Replicating certain mechanisms of in-vitro drug release
  • Determining if drug behavior meets regulatory standards
  • Dissolution simulation when choosing pharmaceutical excipients

Examples of Pharmaceutical Dissolution Equipment

Paddle apparatus dissolution testing is used to simulate tablet behavior in the gastrointestinal tract. The release behavior of implants and transdermal medications can also be tested with dissolution equipment. The reciprocating cylinder dissolution apparatus ("Bio-Dis") is excellent for examining the dissolution behavior of extended release products. Dissolution analysis is key in determining the homogeneity of the final pharmaceutical product. Whether controlled by the bench user or fully automated, the implementation of a dissolution testing protocol is crucial in the final stages of drug development to ensure the efficacy, safety, and marketability of the final compound.
  • Cambrex Breaks Ground on $120M Charles City Expansion

    Thursday, November 05, 2026
    Cambrex has broken ground on a $120 million expansion at its Charles City, Iowa facility. The project will add 160,000 liters of manufacturing capacity, increasing the site's total capacity by approximately 25% to nearly one million liters. read more
  • Alcami Promotes Robert Tragas to VP, Laboratory Services

    Thursday, November 05, 2026
    Alcami has promoted Robert Tragas to Vice President, Laboratory Services. In his expanded role, Tragas will lead laboratory operations across the CDMO's Research Triangle Park campus, overseeing analytical, biologics, microbiology and environmental monitoring functions. read more
  • Samsung Biologics Earns 'Negligible Risk' ESG Rating

    Thursday, November 05, 2026
    Samsung Biologics has achieved a 'Negligible Risk' rating in the latest Morningstar Sustainalytics ESG Risk Ratings assessment. The CDMO received an ESG Risk Rating score of 9.0, advancing from its previous 'Low Risk' rating to 'Negligible Risk,' the lowest of five risk categories. read more
  • Pyramid Pharma Services Adds 13th Commercial Product

    Thursday, November 05, 2026
    Pyramid Pharma Services has expanded a partnership with a longstanding biopharmaceutical customer to manufacture its 13th commercial product: a cartridge-based presentation of a therapy approved to treat rare blood cancers. read more
  • Support your ADC program progression with expert insight

    Wednesday, November 04, 2026
    ADCs are transforming cancer therapy but manufacturing them is complex. Pfizer CentreOne's experts share actionable insights to help accelerate your program. Download the whitepaper today. read more
We're sorry, no matching articles were found. Please select different filter options and try your search again.
We're sorry, no matching articles were found. Please select different filter options and try your search again.